Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M

Scienture (SCNX) announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions, Bonum Health, and Softell. to Tollo Health, Inc. for a total consideration of $5M. The divestitures are part of a broader strategic realignment at the Company designed to sharpen operational focus and unlock long-term value. It is aligned with the Company’s commitment to streamline its core operations, optimize its portfolio, and accelerate growth in the Branded and Specialty Pharma markets. The Company intends to use the proceeds obtained from the divestment to facilitate the high-growth commercial and strategic product development activities at its Scienture subsidiary. The Company believes that the key benefits of the divestitures include: Increased Operational Efficiency: Streamlining the Company’s structure aimed at strengthening its balance sheet, providing for leaner operations and a more agile decision-making framework. Realize Synergies: Consolidating overlapping functions and eliminating redundancies intended to cause annualized cost savings. Dedicated Focus: Affording the full focus and deployment of resources to the commercial products and the high value product pipeline in development at its Scienture subsidiary.